BioNTech and CEPI Boost Africa’s Vaccine Production

BioNTech SE (BNTX) has released an update.

BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) are expanding their partnership, investing up to $145 million to advance mRNA vaccine development in Africa. The initiative aims to establish a Kigali, Rwanda-based facility for research, clinical trials, and manufacturing of vaccines like malaria, tuberculosis, and HIV, prioritizing affordable access to African and low-middle-income countries. This collaboration supports Africa’s goal to produce 60% of its vaccines by 2040 and strengthens pandemic preparedness and health equity in the region.

For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.